Earlier immunohistochemistry studies using TMAs and large sections examining 20–119 breast cancers reported frequencies of p16 positivity ranging from 56% to 89% (TMA) and 21% to 51% (large sections) [8, 9, 19–23]. This evidence concerns the gene CDKN2A and breast carcinoma.